Please login to the form below

Not currently logged in
Email:
Password:

BioCryst

This page shows the latest BioCryst news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

CHMP round-up. At its meeting last week, the CHMP also backed approval of Ammtek’s Amiglidia (glibenclamide) as the first-ever medicine to treat neonatal diabetes and Biocryst’s Alpivir

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    85. BioCryst Pharmaceuticals/ CSL. RAPIVAB (peramivir injection) for the treatment of influenza (marketed).

  • Pharma deals during October 2012 Pharma deals during October 2012

    150. Covagen / Mitsubishi. Collaboration &licence. Tanabe Fynomer-antibody platform for bispecific proteins (FynomAbs)  . 145+. Presidio / BioCryst. Acquisition. Hepatitis C portfolio (lead product phase I/II).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics